Pulmonary blastomycosis following eculizumab therapy in a lung transplant recipient

Takashi Hirama, Rex Michael Santiago, Rohan John, Cecilia Chaparro

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Objectives: Lung transplant recipients are at risk of developing many kinds of lung infection, such as community-acquired, nosocomial, opportunistic, and endemic. Here, we report a young lung transplant recipient who developed blastomycosis, which had most likely occurred following eculizumab treatment for atypical hemolytic uremia syndrome. We hypothesize that the agent interfering with C5 would influence the immune response against Blastomyces species. Although eculizumab has opened a new era for treatment of atypical hemolytic uremia syndrome and has led to the understanding that complementmediated pathology is needed, the risk of potentially fatal infections by blocking the complement pathway has not been fully elucidated. Careful follow-up and frequent tests to look for infections are needed after using this monoclonal antibody.

Original languageEnglish
Pages (from-to)410-413
Number of pages4
JournalExperimental and Clinical Transplantation
Issue number3
Publication statusPublished - 2020 Jun


  • Blastomyces
  • Hemolytic uremia syndrome
  • Thrombotic microangiopathy


Dive into the research topics of 'Pulmonary blastomycosis following eculizumab therapy in a lung transplant recipient'. Together they form a unique fingerprint.

Cite this